Trial · NCT06284122
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT06284122, Phase 3, Active not recruiting, The Lymphoma Academic Research Organisation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5. Trials, record NCT06284122. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06284122
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
- NCT number
- NCT06284122
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 790 participants, estimated
- Lead sponsor
- The Lymphoma Academic Research Organisation
- Conditions
- Follicular Lymphoma
- Interventions
- Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Rituximab, Obinutuzumab, Bendamustin
- First posted
- 2024-02-28
- Last updated
- 2026-09-25
Source ClinicalTrials.gov
Registered outcomes37
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | 130 PFS events assessed by an Independent Review Committee (IRC) (4.6 years) | time from randomization to the date of first documented disease progression/relapse or death from any cause, by Lugano 2014 |
| Primary | Progression Free Survival (PFS) | 173 PFS events assessed by IRC (5.8 y) | time from randomization to the date of first documented disease progression/relapse or death from any cause, by Lugano 2014 |
| Secondary | Overall Response (OR) | 6 months | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Complete Metabolic Rate (CMR) | 6 months | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Overall Response (OR) | 12 months | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Complete Metabolic Rate (CMR) | 12 months | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Overall Response (OR) and Complete Response (CR) rate at EOT | 4.6 years | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Best Overall Response (CR or PR) rate | 5.8 years | by Lugano 2014 (PET-CT based response), assessed by investigator and IRC |
| Secondary | Progression of disease within 2 years (POD24) | 2 years | rate of progression of disease (POD) within 2 years of first line therapy |
| Secondary | PFS | 4.6 years | by Lugano 2014, assessed by investigator |
1 to 10 of 37Source ClinicalTrials.gov
See all 37 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06284122
GET https://conductscience.org/api/trials/v1/NCT06284122/registered?page=2